Search Results for "Kadcyla"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Kadcyla. Results 1 to 2 of 2 total matches.
See also: ado-trastuzumab emtansine
Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Sep 16, 2013 (Issue 1425)
Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer ...
Ado-trastuzumab emtansine (Kadcyla – Genentech), a
human epidermal growth factor receptor 2 (HER2)-targeted
antibody and microtubule inhibitor conjugate, has
been approved by the FDA for intravenous (IV) treatment
of HER2-positive metastatic breast cancer in
patients previously treated with trastuzumab (Herceptin)
and a taxane. The prefix was added to the new conjugate’s
name at the request of the FDA to distinguish it
from trastuzumab.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
; Kadcyla), a HER2-targeted antibody conjugated to the microtubule inhibitor DM1, is usually the preferred ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.